Balyasny Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-19,921
| Closed | -$1.17M | – | 3259 |
|
|
2023
Q4 | $1.17M | Sell |
19,921
-755,826
| -97% | -$42.5M | ﹤0.01% | 1621 |
|
|
2023
Q3 | $33.8M | Buy |
+775,747
| New | +$27.7M | 0.07% | 384 |
|
|
2023
Q2 | – | Sell |
-60,724
| Closed | -$2.26M | – | 3032 |
|
|
2023
Q1 | $2.26M | Buy |
60,724
+15,183
| +33% | +$683K | 0.01% | 1412 |
|
|
2022
Q4 | $2.06M | Buy |
+45,541
| New | +$2.95M | 0.01% | 1388 |
|
|
2021
Q1 | – | Sell |
-77,464
| Closed | -$17M | – | 2155 |
|
|
2020
Q4 | $17M | Buy |
+77,464
| New | +$16.7M | 0.09% | 301 |
|
|
2020
Q1 | – | Sell |
-4,645
| Closed | -$599K | – | 1609 |
|
|
2019
Q4 | $599K | Buy |
+4,645
| New | +$448K | ﹤0.01% | 972 |
|
|
2019
Q1 | – | Sell |
-75,166
| Closed | -$3.19M | – | 1725 |
|
|
2018
Q4 | $3.19M | Buy |
75,166
+24,434
| +48% | +$974K | 0.02% | 599 |
|
|
2018
Q3 | $2.39M | Buy |
+50,732
| New | +$2.82M | 0.01% | 927 |
|
|
2018
Q1 | – | Sell |
-12,300
| Closed | -$224K | – | 2406 |
|
|
2017
Q4 | $224K | Sell |
12,300
-9,300
| -43% | -$144K | ﹤0.01% | 1853 |
|
|
2017
Q3 | $253K | Buy |
+21,600
| New | +$125K | ﹤0.01% | 1607 |
|
|
2016
Q1 | – | Sell |
-8,020
| Closed | -$253K | – | 1580 |
|
|
2015
Q4 | $253K | Buy |
+8,020
| New | +$283K | ﹤0.01% | 1021 |
|
|
2015
Q2 | – | Sell |
-52,342
| Closed | -$1.53M | – | 1375 |
|
|
2015
Q1 | $1.53M | Buy |
+52,342
| New | +$1.23M | 0.01% | 659 |
|
Other funds holding MRTX
Balyasny Asset Management's MRTX Position: Q1 2024 in Review
Balyasny Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 19,921 shares — an estimated $1.17M sold.
Balyasny Asset Management first reported a position in MRTX in Q1 2015 and held it in 12 quarters. The position peaked at $33.8M in Q3 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.
- Balyasny Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Balyasny Asset Management sold 19,921 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.17M.
- Balyasny Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2015 and held it in 12 quarters.
- Balyasny Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $33.8M in Q3 2023.
- 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Balyasny Asset Management's 13F filing for Q1 2024, filed 13 May 2024.